JP2024516748A5 - - Google Patents
Info
- Publication number
- JP2024516748A5 JP2024516748A5 JP2024508815A JP2024508815A JP2024516748A5 JP 2024516748 A5 JP2024516748 A5 JP 2024516748A5 JP 2024508815 A JP2024508815 A JP 2024508815A JP 2024508815 A JP2024508815 A JP 2024508815A JP 2024516748 A5 JP2024516748 A5 JP 2024516748A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cancer
- approximately
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901227 | 2021-04-26 | ||
| AU2021901226A AU2021901226A0 (en) | 2021-04-26 | EGFRvIII BINDING PROTEINS II | |
| AU2021901226 | 2021-04-26 | ||
| AU2021901227A AU2021901227A0 (en) | 2021-04-26 | EGFRvIII BINDING PROTEINS I | |
| PCT/AU2022/050379 WO2022226584A1 (en) | 2021-04-26 | 2022-04-26 | EGFRvIII BINDING PROTEINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516748A JP2024516748A (ja) | 2024-04-16 |
| JP2024516748A5 true JP2024516748A5 (enExample) | 2025-04-22 |
Family
ID=83846542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508815A Pending JP2024516748A (ja) | 2021-04-26 | 2022-04-26 | ＥＧＦＲｖＩＩＩ結合タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240207407A1 (enExample) |
| EP (1) | EP4330285A4 (enExample) |
| JP (1) | JP2024516748A (enExample) |
| AU (1) | AU2022267410A1 (enExample) |
| WO (1) | WO2022226584A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240005794A (ko) * | 2021-05-18 | 2024-01-12 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항 pd-1 폴리펩티드 및 그의 용도 |
| WO2025080980A1 (en) * | 2023-10-13 | 2025-04-17 | The General Hospital Corporation | Treating glioblastoma using car-t cell therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6647868B2 (ja) * | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| AR099812A1 (es) * | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
| WO2016016341A1 (en) * | 2014-07-29 | 2016-02-04 | Cellectis | EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY |
| WO2020172553A1 (en) * | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| CN113853388B (zh) * | 2019-03-27 | 2024-07-19 | 加拿大国家研究委员会 | 抗-egfrviii抗体及其抗原结合片段 |
-
2022
- 2022-04-26 AU AU2022267410A patent/AU2022267410A1/en not_active Abandoned
- 2022-04-26 JP JP2024508815A patent/JP2024516748A/ja active Pending
- 2022-04-26 US US18/288,475 patent/US20240207407A1/en active Pending
- 2022-04-26 EP EP22794091.3A patent/EP4330285A4/en active Pending
- 2022-04-26 WO PCT/AU2022/050379 patent/WO2022226584A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520788A5 (enExample) | ||
| JP2022523781A5 (enExample) | ||
| IL295604A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| JP2021534783A5 (enExample) | ||
| RU2017105161A (ru) | Лечение рака с использованием химерного антигенного рецептора cll-1 | |
| JP2017530694A5 (enExample) | ||
| JP7527641B2 (ja) | スイッチ分子及びスイッチャブルキメラ抗原受容体 | |
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| JP2024539506A5 (enExample) | ||
| CA3032581A1 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| JP2017522879A5 (enExample) | ||
| JP2019516352A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| IL298326A (en) | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same | |
| EP4034245A1 (en) | Trivalent binding molecules | |
| KR20230042753A (ko) | Egfr을 표적화하는 항체 및 그의 용도 | |
| JP2022551757A5 (enExample) | ||
| JP2024532482A5 (enExample) | ||
| JP2021530233A5 (enExample) | ||
| JP2022538425A5 (enExample) | ||
| JP2024516748A5 (enExample) | ||
| JP2023518930A5 (enExample) | ||
| US20250051443A1 (en) | Anti-cd3 monoclonal antibodies and therapeutic constructs | |
| JP2023516067A5 (enExample) |